Related Experiment Video
Updated: Jun 24, 2026
04:47
Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis
Published on: October 27, 2023
Adalimumab for rheumatoid arthritis
Paraskevi V Voulgari1, Alexandros A Drosos
1University of Ioannina Medical School, Rheumatology Clinic, Department of Internal Medicine, 45110 Ioannina, Greece. pvoulgar@cc.uoi.gr
Expert Opinion on Biological Therapy
|January 17, 2007
Summary
Adalimumab effectively treats rheumatoid arthritis by blocking tumor necrosis factor-alpha (TNF-alpha). This biologic therapy demonstrates significant efficacy, improves quality of life, and inhibits joint damage progression in patients.
Area of Science:
- Immunology
- Rheumatology
- Molecular Biology
Background:
- Rheumatoid arthritis (RA) pathogenesis involves pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-alpha).
- Anti-TNF-alpha biological agents represent a significant therapeutic advancement for RA.
- Adalimumab is a fully human monoclonal antibody targeting TNF-alpha.
Purpose of the Study:
- To review recent data on Adalimumab for rheumatoid arthritis treatment.
- To summarize Adalimumab's efficacy, safety, and impact on disease progression.
Main Methods:
- Review of placebo-controlled trials and clinical data.
- Analysis of Adalimumab as monotherapy and in combination with disease-modifying antirheumatic drugs (DMARDs).
Main Results:
- Adalimumab demonstrated significant efficacy in RA patients.
- Well-tolerated as monotherapy or with concomitant DMARDs like methotrexate.
- Significantly inhibited radiographic progression of joint damage.
- Improved patient quality of life.
Conclusions:
- Adalimumab is an effective and well-tolerated treatment for rheumatoid arthritis.
- It offers benefits in disease control, structural joint protection, and quality of life.
- Supports the role of anti-TNF-alpha therapy in RA management.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...